CN114615996A - 通过溶瘤腺病毒、cdk4/6抑制剂和其他治疗活性剂的组合治疗肿瘤 - Google Patents
通过溶瘤腺病毒、cdk4/6抑制剂和其他治疗活性剂的组合治疗肿瘤 Download PDFInfo
- Publication number
- CN114615996A CN114615996A CN202080070210.1A CN202080070210A CN114615996A CN 114615996 A CN114615996 A CN 114615996A CN 202080070210 A CN202080070210 A CN 202080070210A CN 114615996 A CN114615996 A CN 114615996A
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- adenovirus
- cells
- combination
- cdk4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19000396.2 | 2019-09-05 | ||
| EP19000396 | 2019-09-05 | ||
| EP19000406.9 | 2019-09-12 | ||
| EP19000406 | 2019-09-12 | ||
| PCT/EP2020/074980 WO2021044061A1 (en) | 2019-09-05 | 2020-09-07 | Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114615996A true CN114615996A (zh) | 2022-06-10 |
Family
ID=72428285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080070210.1A Pending CN114615996A (zh) | 2019-09-05 | 2020-09-07 | 通过溶瘤腺病毒、cdk4/6抑制剂和其他治疗活性剂的组合治疗肿瘤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220354911A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4025229A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7834342B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220079551A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114615996A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020342594A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3152965A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021044061A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4578943A4 (en) * | 2022-08-25 | 2026-02-25 | Fujifilm Corp | PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1655827A (zh) * | 2002-05-27 | 2005-08-17 | 佩尔·松内·霍尔姆 | 腺病毒和编码其的核酸的新应用 |
| US20170202893A1 (en) * | 2014-09-24 | 2017-07-20 | Salk Institute For Biological Studies | Oncolytic tumor viruses and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| ES2188985T3 (es) | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO2012022496A2 (en) * | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| SG11201507393TA (en) * | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| RU2670762C2 (ru) * | 2013-12-31 | 2018-10-25 | Хуаньчжу Фарма Ко., Лтд. | Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака |
| JP2017516862A (ja) * | 2014-05-30 | 2017-06-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節物質及びその使用方法 |
| CN107849111B (zh) * | 2015-05-04 | 2022-02-22 | Vcn生物科学有限公司 | 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途 |
| WO2018195202A1 (en) * | 2017-04-21 | 2018-10-25 | Pellficure Pharmaceuticals Inc. | Compositions and methods for the treatment of cancer |
| CA3066778A1 (en) * | 2017-06-21 | 2018-12-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| SG11202007873VA (en) * | 2018-03-05 | 2020-09-29 | Klinikum Rechts Der Isar Der Technischen Univ Muenchen | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
-
2020
- 2020-09-07 WO PCT/EP2020/074980 patent/WO2021044061A1/en not_active Ceased
- 2020-09-07 EP EP20768332.7A patent/EP4025229A1/en active Pending
- 2020-09-07 KR KR1020227011226A patent/KR20220079551A/ko active Pending
- 2020-09-07 CA CA3152965A patent/CA3152965A1/en active Pending
- 2020-09-07 AU AU2020342594A patent/AU2020342594A1/en active Pending
- 2020-09-07 US US17/640,720 patent/US20220354911A1/en active Pending
- 2020-09-07 CN CN202080070210.1A patent/CN114615996A/zh active Pending
- 2020-09-07 JP JP2022514645A patent/JP7834342B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1655827A (zh) * | 2002-05-27 | 2005-08-17 | 佩尔·松内·霍尔姆 | 腺病毒和编码其的核酸的新应用 |
| US20170202893A1 (en) * | 2014-09-24 | 2017-07-20 | Salk Institute For Biological Studies | Oncolytic tumor viruses and methods of use |
Non-Patent Citations (4)
| Title |
|---|
| ASHISH P. SHAH等: "A Review on DNA Repair Inhibition by PARP inhibitors in cancer Therapy", 《FOLIA MEDICA》 * |
| MONTSERRAT PEREZ-SALVIA等: "Bromodomain inhibitors and cancer therapy: From structures to applications", 《EPIGENETCS》 * |
| NADIIA LYPOVA等: "Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy", 《CANCERS》 * |
| YUJUN ZHAO 等, SMALL-MOLECULE INHIBITORS OF THE MDM2-P53 PROTEIN-PROTEIN INTERACTION (MDM2 INHIBITORS) IN CLINICAL TRIALS FOR CANCER TREATMENT * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022547885A (ja) | 2022-11-16 |
| AU2020342594A1 (en) | 2022-03-10 |
| CA3152965A1 (en) | 2021-03-11 |
| JP7834342B2 (ja) | 2026-03-24 |
| WO2021044061A1 (en) | 2021-03-11 |
| US20220354911A1 (en) | 2022-11-10 |
| KR20220079551A (ko) | 2022-06-13 |
| EP4025229A1 (en) | 2022-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025013934A (ja) | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 | |
| EA028590B1 (ru) | Ингибиторы мет для повышения эффективности лучевой терапии | |
| Vaughan et al. | p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity | |
| Zhang et al. | EGF receptor signaling modulates YAP activation and promotes experimental proliferative vitreoretinopathy | |
| Zeng et al. | Adenovirus early region 3 RIDα protein limits NFκB signaling through stress-activated EGF receptors | |
| US20220280590A1 (en) | Use of inhibitors of yap and sox2 for the treatment of cancer | |
| Holzmüller et al. | YB‐1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma | |
| US11911450B2 (en) | Method for managing pain | |
| Cheng et al. | Reduced expression of PDZK1 mediates fibroblast activation and cardiac fibrosis via EGFR phosphorylation in diabetic cardiomyopathy | |
| JP7834342B2 (ja) | 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 | |
| Song et al. | Cardiomyocyte‐specific overexpression of FPN1 diminishes cardiac hypertrophy induced by chronic intermittent hypoxia | |
| Xing et al. | A dual-peptides and specific promoter-modified nano gene delivery system for myocardial hypertrophy treatment | |
| RU2835886C1 (ru) | Лечение опухолей комбинацией онколитического аденовируса, ингибитора cdk4/6 и дополнительного терапевтического агента | |
| RU2811278C2 (ru) | Лечение опухолей комбинацией онколитического аденовируса и ингибитора cdk4/6 | |
| US20130157959A1 (en) | Use of hades as tumor suppressor target | |
| Guo et al. | Antiglioma effects of combined use of a baculovirual vector expressing wild‐type p53 and sodium butyrate | |
| Zang et al. | Chromatin remodeling factor CHRAC1 regulates doxorubicin-induced cardiotoxicity via IRF9/GSDMD/CASP-1 | |
| US20100311809A1 (en) | Viral vector system, a composition comprising the viral vector system and its use | |
| CN102056631A (zh) | 细胞凋亡诱导物 | |
| Cai et al. | Overexpression of GJB1–13k induces mitochondrial calcium overload and triggers apoptosis and GSDME-mediated pyroptosis in cervical cancer | |
| Dong et al. | Intravitreal delivery of LATS1 mRNA by lipid nanoparticles as an effective strategy for uveal melanoma therapy | |
| Yang et al. | YBX1 Modulated Corneal Neovascularization Induced by Alkali Burn via m5C-Dependent Regulation of the STAT3/HIF-1α/VEGFA Axis | |
| Kankanamge et al. | Nrf1 coordinates proteasome activity and autophagy to maintain cardiac proteostasis | |
| WO2025097153A1 (en) | Fam222a as a therapeutic target | |
| JP2024542196A (ja) | 黄斑変性症を処置するための材料及び方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220610 |